Lipids & Metabolic

Researchers at the University of Georgia have uncovered 27 new metabolites associated with arterial stiffness, according to work published in the American Journal of Hypertension.

A Harvard cardiologist and his team have developed an experimental genetic test for predicting obesity, NPR reports.

Intensive therapy to keep blood pressure (BP) levels below 130/80 mmHg helped lower the risk for heart attacks, strokes and other CV complications in patients with concomitant type 2 diabetes and hypertension, researchers have found.

The FDA has expanded Praluent’s (alirocumab) regulatory approval to reflect the reduced risk of heart attack, stroke and unstable angina evidenced in 2018’s ODYSSEY OUTCOMES trial—a move announced the same day drugmaker Sanofi released its first-quarter earnings, which were lower than expected.

Two studies published April 18 in the journal Cell have shined new light on the role genetics can play in developing obesity—or protecting against it.

The popular diabetes drug metformin reversed left ventricular hypertrophy (LVH) in a randomized trial of patients with coronary artery disease but without diabetes, suggesting a potential new use for the medication.

The FDA has cleared Gelesis100 hydrogel capsules to be used as a weight management aid alongside diet and exercise in adults with body mass indexes (BMIs) ranging from 25 to 40, according to an April 14 press release from the product’s manufacturer.

The FDA’s decision to mandate labeling of added sugar content on packaged foods and beverages is estimated to prevent nearly 1 million cases of diabetes and cardiovascular disease over the next 20 years and save the U.S. $31 billion in net healthcare costs over that timeframe.

French drugmaker Sanofi announced on April 10 a plan to lower its insulin prices to $99 per month for some U.S. patients, beginning in June. The announcement came amid a series of congressional hearings about drug costs and was met with questions about why this move and other recent cost-cutting measures took so long.

People diagnosed with type 2 diabetes at 40 or younger were about twice as likely to die over 5.6 years of follow-up compared to age-matched controls, according to a registry study from Sweden. But the relationship weakened substantially as the age of onset progressed, such that patients diagnosed in their 80s carried no excess mortality risk.

Medtronic has struck a value-based agreement with Blue Cross and Blue Shield of Minnesota in which the medical device company will pay back the insurer if patients using the Guardian Connect continuous glucose monitoring (CGM) system fail to keep their blood sugar levels within a specified range.

Dietary risk factors—such as consuming too much sodium or not enough whole grains and fruits—were responsible for 11 million deaths globally in 2017, according to a new analysis in The Lancet.